부산대학교 도서관

To link to full-text access for this article, visit this link: http://dx.doi.org/10.1016/j.trsl.2009.08.006 Byline: Philip L. Simonian (a), Christina L. Roark (b), Willi K. Born (b), Rebecca L. O'Brien (b), Andrew P. Fontenot (a)(b) Abbreviations: HP, hypersensitivity pneumonitis; MHC, major histocompatibility complex; IFN-[gamma], interferon-[gamma]; IL-5, interleukin-5; TGF-[beta], tumor growth factor-[beta]; Th1, T-helper 1 Abstract: Hypersensitivity pneumonitis (HP) is an inflammatory lung disease caused by the repeated inhalation of aerosolized antigens. With chronic exposure to an inhaled antigen, patients are at risk of developing irreversible pulmonary fibrosis as well as an increased morbidity and mortality. Although [alpha][beta] T cells have been shown to be important in the pathogenesis of HP, [gamma][delta] T cells also accumulate in the bronchoalveolar lavage of patients with HP. [gamma][delta] T cells represent a distinct lymphocyte subset, whose primary function is not well understood. In contrast to [alpha][beta] T cells, [gamma][delta] T cells recognize unprocessed antigens, such as those upregulated on injured or stressed epithelial cells. In a murine model of HP induced by exposure to the ubiquitous microorganism Bacillus subtilis, [gamma][delta] T cells expressing the canonical V[gamma]6/V[delta]1 T cell receptor were dramatically expanded in the lung. The predominant cytokines expressed by this [gamma][delta] T-cell subset were T-helper 17 (Th17) cytokines that were critical for bacterial clearance and the resolution of lung inflammation. Th17-expressing [gamma][delta] T cells are also expanded in other murine models of lung infection and inflammation, which suggests that these cells play a sentinel role in mucosal immunity. Thus, an increased understanding of [gamma][delta] T cells that express Th17 cytokines in HP and other inflammatory lung diseases may lead to the development of novel therapeutic and clinical strategies that prevent the development of fibrotic lung disease. Author Affiliation: (a) Department of Medicine, University of Colorado Denver, Aurora, Colo (b) Integrated Department of Immunology, National Jewish Health, Denver, Colo Article History: Received 23 January 2009; Accepted 29 July 2009 Article Note: (footnote) Supported by Grants HL62410 and ES011810 (to A.P.F.) and HL89766 (to P.L.S.) from the National Institutes of Health.